FLUDEOXYGLUCOSE
Major Depressive Disorder (MDD)
National Taiwan University HospitalSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Major Depressive Disorder (MDD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[18F] VAT Stony Brook University | Phase 4 | B |
Ammoxetine CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | B |
ABP-688 Stony Brook University | Phase 4 | B |
LEVOMILNACIPRAN HYDROCHLORIDE Zhejiang Huahai Pharmaceutical Co., Ltd. | Phase 3 | B |
Milsaperidone Vanda Pharmaceuticals | Phase 3 | B |
View all 26 →
Same molecule, other indications
FLUDEOXYGLUCOSE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →